# David S. Shames

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/david-s-shames/

## Facts

| Field | Value |
| --- | --- |
| Citations | 20,009 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 65 |
| i10-index | 108 |
| OpenAlex ID | https://openalex.org/A5049192558 |
| ORCID iD | https://orcid.org/0000-0002-5900-1177 |
| Works | 330 |

## Researcher papers

- [First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer](https://scholariq.org/papers/first-line-atezolizumab-plus-chemotherapy-in-extensive-stage-small-cell-lung/)
- [Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer](https://scholariq.org/papers/comprehensive-genomic-analysis-identifies-sox2-as-a-frequently-amplified-gene-in/)
- [Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities](https://scholariq.org/papers/patterns-of-transcription-factor-programs-and-immune-pathway-activation-define/)
- [Detection and Dynamic Changes of <i>EGFR</i> Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy](https://scholariq.org/papers/detection-and-dynamic-changes-of-i-egfr-i-mutations-from-circulating-tumor-dna/)
- [Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung](https://scholariq.org/papers/results-from-the-phase-iii-randomized-trial-of-onartuzumab-plus-erlotinib-versus/)
- [Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)](https://scholariq.org/papers/differential-regulation-of-pd-l1-expression-by-immune-and-tumor-cells-in-nsclc/)
- [Metabolic Diversity in Human Non-Small Cell Lung Cancer Cells](https://scholariq.org/papers/metabolic-diversity-in-human-non-small-cell-lung-cancer-cells-2/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [RNA modifications and cancer](https://scholariq.org/topics/rna-modifications-and-cancer/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.